System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Elisabetta Bugianesi is an expert in Hepatology at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (Italy). As of October 2026, ScienceLeadR ranks Elisabetta Bugianesi in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Insulin Resistance. Elisabetta Bugianesi has authored 704 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 4 of them ongoing. SLR score: 2,918 (community average: 125). How the SLR is computed.

LeadR Profile

Elisabetta Bugianesi Azienda Ospedaliera Citta' della Salute e della Scienza di Torino Italy
2 918 ScienceLeadR Reputation 2918

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026
Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 704

Citations

Citations: 67 193 1st author: 29 Last author: 161 Unique author: 8

Main journals

J Hepatol 185
Dig Liver Dis 116
Hepatology 52
Clin Gastroenterol Hepatol 21
Gastroenterology 19

Best Journals

J Hepatol 58
Nat Rev Gastroenterol Hepatol 7
Gastroenterology 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity.
PMID 42925568 — depression, quality of life, sleep, non-alcoholic fatty liver disease, signs and symptoms, pruritus, fatigue, work, prevalence, sleep initiation and maintenance disorders		J Clin Gastroenterol20260
Beyond BCLC and AFP: A Circulating IL-6/IL-8 Inflammatory Signature Refines Survival Prediction in Hepatocellular Carcinoma.
PMID 42864653 — cytokines, carcinoma, hepatocellular, interleukin-6, interleukin-8, liver, diagnosis, prognosis		Immunology20260
Stratified Use of Genetic Testing in Liver Disease Improves Diagnostic Yield and Clinical Impact.
PMID 42737803 — liver diseases, research design, genetic testing, workflow, liver, diagnosis, child		Int J Mol Sci20260
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
PMID 42617506 — liver diseases, multiple chronic conditions, liver		JHEP Rep20264
Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: A randomized controlled trial.
PMID 42331287 — liver, diet, food, weight loss, metabolic syndrome, food, processed, dietary patterns		JHEP Rep20261

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 6
Phase 3 6
N/A 3
Phase 4 1

By status:

Completed 8
Recruiting 4
Active not recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 14
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 6

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH)
2024-512895-36-00 — safety, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS